Stockscreener 앱 받기
1.21
3.97%
-0.05
시간 외 거래:
1.21
전일 마감가:
$1.26
열려 있는:
$1.18
하루 거래량:
1.55M
Relative Volume:
1.07
시가총액:
$342.75M
수익:
-
순이익/손실:
$-125.04M
주가수익비율:
-1.4756
EPS:
-0.82
순현금흐름:
$-122.99M
1주 성능:
-21.94%
1개월 성능:
-5.47%
6개월 성능:
-50.61%
1년 성능:
-44.24%
1일 변동 폭
$1.17
$1.265
1주일 범위
$1.04
$1.55
52주 변동 폭
$1.04
$3.45
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
ERAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.21 | 342.75M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Teacher Retirement System of Texas Buys 12,345 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Insiders Lose Out As Stock Sinks To US$1.21 - simplywall.st
Erasca stock hits 52-week low at $1.23 amid market challenges - Investing.com India
Erasca (NASDAQ:ERAS) Coverage Initiated by Analysts at Raymond James - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Swiss National Bank - Defense World
Erasca (NASDAQ:ERAS) Now Covered by Analysts at Raymond James - Defense World
Raymond James sets $5 target for Erasca stock, cites valuation gap By Investing.com - Investing.com South Africa
Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation - Nasdaq
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Raymond James sets $5 target for Erasca stock, cites valuation gap - Investing.com India
Raymond James Initiates Erasca at Outperform With $5 Price Target - MarketScreener
Erasca initiated with an Outperform at Raymond James - TipRanks
Charles Schwab Investment Management Inc. Buys 39,066 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting - The Manila Times
Game-Changing Cancer Treatments: Erasca Reveals 3 Novel Drug Breakthroughs at AACR 2025 - Stock Titan
Bank of New York Mellon Corp Grows Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
What is HC Wainwright’s Estimate for Erasca FY2029 Earnings? - Defense World
The Goldman Sachs Group Has Lowered Expectations for Erasca (NASDAQ:ERAS) Stock Price - Defense World
Erasca (NASDAQ:ERAS) Earns “Buy” Rating from HC Wainwright - Defense World
Erasca, Inc. Reports 2024 Financial and Strategic Progress - TipRanks
Erasca Inc. (ERAS) reports earnings - Quartz
ERASCA Earnings Results: $ERAS Reports Quarterly Earnings - Nasdaq
Erasca, Inc. SEC 10-K Report - TradingView
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results - The Manila Times
Erasca's $440M War Chest Powers Two Groundbreaking Cancer Drugs Into 2025 Trials - StockTitan
Erasca (ERAS) Expected to Announce Earnings on Wednesday - Defense World
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) Price Target at $5.70 - Defense World
Morgan Stanley Reaffirms Overweight Rating for Erasca (NASDAQ:ERAS) - Defense World
Rhumbline Advisers Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge - TipRanks
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by New York State Common Retirement Fund - Defense World
Erasca stock hits 52-week low at $1.32 amid market challenges - Investing.com Australia
Erasca Inc Still Hasn’t Convinced Analysts? - Stocks Register
Erasca stock hits 52-week low at $1.5 amid market challenges - Investing.com Australia
Erasca stock hits 52-week low at $1.5 amid market challenges By Investing.com - Investing.com South Africa
Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Investor’s Toolkit: Key Ratios for Assessing Erasca Inc (ERAS)’s Performance - The Dwinnex
Erasca Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Erasca Inc [ERAS] Records 200-Day SMA of $2.5522 - Knox Daily
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
BlackBerry Ltd [BB] Records 200-Day SMA of $2.77 - Knox Daily
Erasca (NASDAQ:ERAS) Stock Price Down 6.1%What's Next? - MarketBeat
Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex
Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News
Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha
What Are You Thinking About Investing In Erasca Inc (NASDAQ: ERAS) Stock? - Stocks Register
Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):